Literature DB >> 16297802

Autologous skeletal myoblast transplantation improved hemodynamics and left ventricular function in chronic heart failure dogs.

Kun-Lun He1, Geng-Hua Yi, Warren Sherman, Hua Zhou, Ge-Ping Zhang, Anguo Gu, Race Kao, Howard B Haimes, John Harvey, Eric Roos, Desmond White, Doris A Taylor, Jie Wang, Daniel Burkhoff.   

Abstract

BACKGROUND: Previous studies have suggested that autologous skeletal myoblast transplantation (ASMT) improves left ventricular (LV) function in small animals after myocardial infarction. We tested the effects of ASMT on hemodynamics, LV function and remodeling in coronary microembolization-induced chronic heart failure (CHF) in conscious dogs.
METHODS: Nineteen dogs were continuously instrumented with LV pressure sensors and mid-myocardial sonomicrometry crystals for dP/dt(max) and LV volume determination. Each dog underwent baseline assessment in a conscious state. CHF (20% to 30% reduction in dP/dt(max) and LV end-diastolic pressure >16 mm Hg) was created by daily coronary microembolizations via a continuously implanted coronary catheter. Skeletal muscle biopsy was performed and myoblasts were isolated and expanded. Then 2.7 x 10(8) to 8.3 x 10(8) myoblasts were injected into the infarcted region of 11 dogs after establishment of CHF. Saline injection (sham) was performed in 8 control dogs. Animals were evaluated every 2 weeks for up to 10 weeks. Global ejection fraction was determined by echocardiography. The end-systolic pressure-end-systolic volume relationship (ESPVR) was analyzed by the Sonomicrometic system.
RESULTS: Compared with saline injection, ASMT significantly increased dP/dt(max) (105 +/- 9% vs 97 +/- 7%, values were expressed as percentage change from baseline CHF, p = 0.013) and ejection fraction (46 +/- 3% vs 40 +/- 2%, p = 0.034) at 10 weeks after myoblast transplantation. There was a significant leftward and upward shift of the ESPVR back toward normal at 10 weeks after myoblast transplantation (p = 0.034). Three animals labeled with BrdU myoblasts showed no histologic evidence of viable engraftment.
CONCLUSIONS: ASMT provided mild improvements in hemodynamics and LV function and reduced LV remodeling in conscious dogs with CHF.

Entities:  

Mesh:

Year:  2005        PMID: 16297802     DOI: 10.1016/j.healun.2005.02.024

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  21 in total

Review 1.  Stem cell therapy for ischemic heart disease.

Authors:  Mohammad Nurulqadr Jameel; Jianyi Zhang
Journal:  Antioxid Redox Signal       Date:  2010-10-28       Impact factor: 8.401

Review 2.  Stem cells and cardiac repair: a critical analysis.

Authors:  Jonathan H Dinsmore; Nabil Dib
Journal:  J Cardiovasc Transl Res       Date:  2008-01-31       Impact factor: 4.132

3.  The real estate of myoblast cardiac transplantation: negative remodeling is associated with location.

Authors:  Jonathan D McCue; Cory Swingen; Tanya Feldberg; Gabe Caron; Adam Kolb; Christopher Denucci; Somnath Prabhu; Randy Motilall; Brian Breviu; Doris A Taylor
Journal:  J Heart Lung Transplant       Date:  2008-01       Impact factor: 10.247

Review 4.  Stem cells in the heart: what's the buzz all about? Part 2: Arrhythmic risks and clinical studies.

Authors:  Rachel Ruckdeschel Smith; Lucio Barile; Elisa Messina; Eduardo Marbán
Journal:  Heart Rhythm       Date:  2008-02-15       Impact factor: 6.343

Review 5.  Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions.

Authors:  Santosh K Sanganalmath; Roberto Bolli
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

6.  Cell transplantation for cardiac regeneration: where do we stand?

Authors:  E J van den Bos; W J van der Giessen; D J Duncker
Journal:  Neth Heart J       Date:  2008       Impact factor: 2.380

7.  Correlations between microRNAs and their target genes in skeletal myoblasts cell therapy for myocardial infarction.

Authors:  Andrea Rognoni; Chiara Cavallino; Francesco Rametta; Angelo Sante Bongo
Journal:  Ann Transl Med       Date:  2016-08

Review 8.  Cardiac cell therapy: where we've been, where we are, and where we should be headed.

Authors:  Konstantinos Malliaras; Eduardo Marbán
Journal:  Br Med Bull       Date:  2011       Impact factor: 4.291

9.  Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 achieves global cardiac gene transfer in canines.

Authors:  Lawrence T Bish; Meg M Sleeper; Benjamin Brainard; Stephen Cole; Nicholas Russell; Elanor Withnall; Jason Arndt; Caryn Reynolds; Ellen Davison; Julio Sanmiguel; Di Wu; Guangping Gao; James M Wilson; H L Sweeney
Journal:  Mol Ther       Date:  2008-09-23       Impact factor: 11.454

10.  MyoCell, a cell-based, autologous skeletal myoblast therapy for the treatment of cardiovascular diseases.

Authors:  Husnain Kh Haider; Ye Lei; Muhammad Ashraf
Journal:  Curr Opin Mol Ther       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.